Mark Socinski

Mark Socinski led the IMpower150 trial demonstrating the efficacy of atezolizumab combined with bevacizumab and chemotherapy for first-line non-squamous NSCLC, including EGFR- and ALK-altered patients. His research has contributed to understanding the interplay between angiogenesis inhibition and immunotherapy in thoracic malignancies. He has been a principal investigator for landmark phase III trials across multiple NSCLC histologies and has championed combination immunotherapy approaches. Socinski is a recognized expert on first-line treatment selection and sequencing in advanced NSCLC.